MedTrace Logo

D3-GHR Polymorphism and Turner Syndrome

NCT00443144 · Status: COMPLETED · Type: OBSERVATIONAL

Last updated 2015-12-03

No results posted yet for this study

Summary

The protein polymorphism of the growth hormone receptor characterized by the genomic deletion of exon 3 has been linked to the magnitude of the first-year-growth response to growth hormone (GH) in girls with Turner syndrome.

Objective: to study the long-term effect of GH therapy in Turner syndrome in correlation to this GHR polymorphism in a mainly retrospective design (chart-review).

Conditions

  • Turner Syndrome
  • Short Stature

Interventions

DRUG

recombinant human growth hormone

Sponsors & Collaborators

  • University Hospital Tuebingen

    lead OTHER

Principal Investigators

  • Gerhard Binder, M.D. PhD · University-Children's Hospital Tübingen

Eligibility

Min Age
38 Months
Max Age
14 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-05-31
Primary Completion
2007-04-30
Completion
2007-05-31

Countries

  • Germany

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00443144 on ClinicalTrials.gov